TriangleNCT00410605 · OUTCOME
Local Cytokine Milieu Using Tissue Micro Arrays of Bone Marrow Biopsy Specimens
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- Not reported
- Unit
- Not reported
- Interval / dispersion
- Not reported
- Time frame
- Up to 5 years
Analysis population: Outcome measure data were not collected.
Groups in this outcome
Bevacizumab, Dexamethasone, and Lenalidomide
Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, oral lenalidomide on days 1-21, and oral dexamethasone on days 1, 8, 15, and 22. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. bevacizumab: Given IV lenalidomide: Given orally dexamethasone: Given orally
| Group | Source count |
|---|---|
| Bevacizumab, Dexamethasone, and Lenalidomide | 0 |
Reported measurements
No numerical measurement classes were posted for this outcome. Missing is not zero.
Complete source fields
- denoms
- counts
- group Id
- OG000
- value
- 0
- units
- Participants
- groups
- description
- Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, oral lenalidomide on days 1-21, and oral dexamethasone on days 1, 8, 15, and 22. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. bevacizumab: Given IV lenalidomide: Given orally dexamethasone: Given orally
- id
- OG000
- title
- Bevacizumab, Dexamethasone, and Lenalidomide
- population Description
- Outcome measure data were not collected.
- reporting Status
- POSTED
- time Frame
- Up to 5 years
- title
- Local Cytokine Milieu Using Tissue Micro Arrays of Bone Marrow Biopsy Specimens
- type
- SECONDARY
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice